AMAG - AMAG Pharmaceuticals, Inc.
15.93 0.00 (0.00%)
After hours: 5:01PM EST
| Previous Close | 16.01 |
| Open | 16.05 |
| Bid | 14.50 x 1300 |
| Ask | 21.00 x 800 |
| Day's Range | 15.80 - 16.20 |
| 52 Week Range | 14.35 - 26.10 |
| Volume | 305,710 |
| Avg. Volume | 570,859 |
| Market Cap | 551.286M |
| Beta (3Y Monthly) | -0.03 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.91 |
| Earnings Date | Feb 25, 2019 - Mar 1, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.58 |
- GlobeNewswire•yesterday
AMAG Pharmaceuticals to Present at Leerink Partners Global Healthcare Conference
WALTHAM, Mass., Feb. 19, 2019 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will present at the Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019. Ted.
- Thomson Reuters StreetEvents•11 days ago
Edited Transcript of AMAG earnings conference call or presentation 7-Feb-19 1:00pm GMT
Q4 2018 AMAG Pharmaceuticals Inc Earnings Call
Motley Fool•12 days agoAMAG Pharmaceuticals (AMAG) Q4 2018 Earnings Conference Call Transcript
AMAG earnings call for the period ending December 31, 2018.
- Zacks•12 days ago
AMAG Q4 Loss Narrower Than Expected, Revenues Lag Estimates
AMAG encourages with narrower-than-expected loss in Q4 while revenues fall shy of estimates.
- Zacks•13 days ago
AMAG Pharmaceuticals (AMAG) Reports Q4 Loss, Misses Revenue Estimates
AMAG Pharmaceuticals (AMAG) delivered earnings and revenue surprises of 38.78% and -2.17%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•13 days ago
AMAG Pharmaceuticals: 4Q Earnings Snapshot
The Waltham, Massachusetts-based company said it had a loss of 64 cents per share. Losses, adjusted to account for discontinued operations, were 60 cents per share. The results beat Wall Street expectations. ...
- GlobeNewswire•13 days ago
AMAG Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update
Reaffirms 2019 Financial Guidance and Announces Consolidation of Women’s Health and Maternal Health Sales Forces Conference Call Scheduled for 8:00 a.m. ET Today WALTHAM,.
- GlobeNewswire•21 days ago
AMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast on Thursday, February 7, 2019 at 8:00 a.m. ET
WALTHAM, Mass., Jan. 30, 2019 -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its fourth quarter and full year 2018 financial results will be released on.
- GlobeNewswire•last month
AMAG Pharmaceuticals Completes Acquisition of Perosphere Pharmaceuticals
AMAG Pharmaceuticals, Inc. (AMAG) announced today that it has completed the previously announced acquisition of Perosphere Pharmaceuticals Inc., a private biopharmaceutical company. Through this acquisition, AMAG adds ciraparantag to its development portfolio. Ciraparantag is in development as a single dose, ready-to-use solution for use in patients treated with novel oral anticoagulants (NOACs) or low molecular weight heparin (LMWH) when reversal of the anticoagulant effect of these products is needed for emergency surgery, urgent procedures or due to life-threatening or uncontrolled bleeding.
- GlobeNewswire•last month
Research Report Identifies Edison International, MPLX LP, Moody's, AMAG Pharmaceuticals, Cross Country Healthcare, and New Mountain Finance with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Jan. 17, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•last month
AMAG Pharmaceuticals Appoints Christine Moulton Clemson, Ph.D., M.S.C.I. as Vice President of Medical Affairs
AMAG Pharmaceuticals, Inc. (AMAG) today announced the appointment of Christine Moulton Clemson, Ph.D., M.S.C.I., as vice president, medical affairs, reporting to Brian Robinson, M.D., senior vice president, medical affairs. Dr. Clemson will serve as a medical lead for AMAG’s women’s healthcare products. “Christine brings broad medical affairs, scientific, and functional leadership experience that will greatly contribute to our expanding medical affairs organization and AMAG’s goal to further grow as a development company,” said Dr. Robinson.
- GlobeNewswire•last month
AMAG Pharmaceuticals Announces Preliminary 2018 Financial Results and Provides 2019 Financial Guidance
AMAG Pharmaceuticals, Inc. (AMAG) today announced preliminary unaudited fourth quarter and full year 2018 financial results and provided 2019 financial guidance. "In 2018, we achieved several key milestones including receiving two approvals from the U.S. Food and Drug Administration (FDA), launching both the Makena subcutaneous auto-injector and Feraheme broad label, and receiving FDA acceptance of our new drug application for VyleesiTM (bremelanotide).
Market Realist•2 months agoSpectrum Pharmaceuticals: Earnings Trends and Recent Developments
In the first nine months of 2018, Spectrum Pharmaceuticals (SPPI) reported a net income and diluted EPS of -$70.8 million and -$0.69, respectively—compared to -$62.7 million and -$0.78 in the same period the previous year.
Market Realist•2 months agoSpectrum Pharmaceuticals: Financial Overview in December
In the first nine months of 2018, Spectrum Pharmaceuticals’ (SPPI) net revenues declined ~20% YoY (year-over-year) to $79.9 million from $99.8 million. During this period, the company’s net product sales were $76.4 million, which reflected an ~13% YoY decline. During the same period, the company’s revenues from license fees and services were $3.5 million, which reflected an ~70% YoY decline.
- Zacks•2 months ago
AMAG Up Nearly 10% in a Year on Label Expansion, Acquisitions
AMAG's (AMAG) share improve 9.7% year to date courtesy of label expansion efforts as well as acquisitions and deals.
- GlobeNewswire•2 months ago
AMAG Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Dec. 19, 2018 -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that William Heiden, president and chief executive officer, will present at the.
- Zacks•2 months ago
AMAG to Acquire Ciraparantag Maker Perosphere Pharmaceuticals
AMAG inks a deal to buy Perosphere Pharmaceuticals, which will add the latter's investigational candidate, ciraparantag, to its portfolio.
- GlobeNewswire•2 months ago
AMAG Pharmaceuticals Enters Into Definitive Merger Agreement to Acquire Perosphere Pharmaceuticals
AMAG Pharmaceuticals, Inc. (AMAG) today announced it has entered into a definitive agreement to acquire Perosphere Pharmaceuticals Inc., a private biopharmaceutical company. Through this acquisition, AMAG will acquire global rights to ciraparantag, a next generation anticoagulant reversal agent, further enhancing its development pipeline and leveraging AMAG’s expertise in hematology.
- Simply Wall St.•3 months ago
Estimating The Fair Value Of AMAG Pharmaceuticals Inc (NASDAQ:AMAG)
Does the December share price for AMAG Pharmaceuticals Inc (NASDAQ:AMAG) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value by estimating the company’s future cash flows and Read More...
GuruFocus.com•3 months agoPaul Tudor Jones Continues to Buy Apple, Alibaba
Guru increased holdings of these 7 stocks
- GlobeNewswire•3 months ago
AMAG Pharmaceuticals Awards Four Grants to Further Research in Preterm Birth and Preeclampsia
WALTHAM, Mass., Nov. 29, 2018 -- As part of the company’s annual grant program to support research to reduce preterm birth and preeclampsia and associated complications, AMAG.
- Zacks•3 months ago
AMAG's Label Expansion of Lead Products Raises Share Price
AMAG's (AMAG) label expansion efforts for Feraheme and Makena are encouraging.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of AMAG earnings conference call or presentation 1-Nov-18 12:00pm GMT
Q3 2018 AMAG Pharmaceuticals Inc Earnings Call
